Novartis AG
USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS
Last updated:
Abstract:
The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
Status:
Application
Type:
Utility
Filling date:
4 Dec 2019
Issue date:
9 Apr 2020